Diagnosis of heparin-induced thrombocytopenia in the Czech Republic

Czech version

Authors: J. Gumulec
Authors‘ workplace: Ústav klinické hematologie FN Ostrava, přednosta prim. MUDr. Jaromír Gumulec
Published in: Vnitř Lék 2012; 58(7 a 8): 128-134
Category: 60th Birthday prof. MUDr. Miroslav Penka, CSc.

Overview

Heparin-induced thrombocytopenia is a prothrombotic adverse effect induced by platelet-activating antibodies against complexes of platelet factor 4 and heparin. Diagnosis rests on a clinical assesment of disease probability and laboratory testing. In this review, I describe some approaches to the evaluation of patients with suspected heparin-induced thrombocytopenia. In conclusion I draw attention to some of the reserves in the diagnostic approaches to this potentially fatal disorder in the Czech Republic.

Key words:
heparin-induced thrombocytopenia – heparin – diagnostic procedure – rapid testing – immunoassay – functional tests

Sources

1. Kelton JG, Sheridan D, Santos A et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72: 925–930.

2. Lindhoff-Last E, Nakov R, Misselwitz F et al. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Br J Haematol 2002; 118: 1137–1142.

3. Greinacher A, Juhl D, Strobel U et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007; 5: 1666–1673.

4. Chong BH, Murray B, Berndt MC et al. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 1994; 83: 1535–1541.

5. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1–7.

6. Warkentin TE, Greinacher A, Koster A et al. American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest 2008; 133 (6 Suppl): 340S–380S.

7. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355: 809–817.

8. Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7 (Suppl 1): 9–12.

9. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286–1292.

10. Greinacher A, Kohlmann T, Strobel U et al. The temporal profile of the anti-PF4/heparin immune response. Blood 2009; 113: 4970–4976.

11. Lubenow N, Kempf R, Eichner A et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002; 122: 37–42.

12. Lo G K, Juhl D, Warkentin TE et al. Evaluation of pretest clinical score (4 T‘s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 759–765.

13. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121: 535–555.

14. Pouplard C, Gueret P, Fouassier M et al. Prospective evaluation of the ‚4Ts‘ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2007; 5: 1373–1379.

15. Cuker A, Arepally G, Crowther MA et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010; 8: 2642–2650.

16. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27–30.

17. Pouplard C, Amiral J, Borg JY et al. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br J Haematol 1997; 99: 273–280.

18. Pouplard C, Amiral J, Borg JY et al. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999; 111: 700–706.

19. Schenk S, El-Banayosy A, Morshuis M et al. IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support. J Thromb Haemost 2007; 5: 235–241.

20. Greinacher A, Michels I, Kiefel V et al. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 734–736.

21. Warkentin TE, Sheppard JA, Moore JC et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005; 146: 341–346.

22. Alberio L, Kimmerle S, Baumann A et al. Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am J Med 2003; 114: 528–536.

23. Juhl D, Eichler P, Lubenow N et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006; 76: 420–426.

24. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005; 127 (2 Suppl): 35S–45S.

25. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002; 126: 1415–1423.

26. Shaheed G, Malkovska V, Mendoza J et al. PF4 ENHANCED assay for the diagnosis of heparin-induced thrombocytopenia in complex medical and surgical patients. Crit Care Med 2007; 35: 1691–1695.

27. Zwicker JI, Uhl L, Huang WY et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004; 2: 2133–2137.

28. Warkentin TE, Sheppard JI, Moore JC et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008; 6: 1304–1312.

29. Whitlatch NL, Perry SL, Ortel TL. Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 2008; 100: 678–684.

30. Warkentin TE, Sheppard JI. No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost 2006; 4: 281–282.

31. Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330–1335.

32. Warkentin TE, Sheppard JA, Moore JC et al. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009; 113: 4963–4969.

33. Warkentin TE, Roberts RS, Hirsh J et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163: 2518–2524.

34. Sachs UJ, von Hesberg J, Santoso S et al. Evaluation of a new nanoparticle-based lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT). Thromb Haemost 2011; 106: 1197–1202.

35. Cuker A. Heparin-induced thrombocytopenia (HIT) in 2011: an epidemic of overdiagnosis. Thromb Haemost 2011; 106: 993–994.

36. Bakchoul T, Giptner A, Bein G et al. Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). Thromb Res 2011; 127: 345–348.

37. Pouplard C, Leroux D, Regina S et al. Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost 2010; 103: 145–150.

38. Morel-Kopp MC, Aboud M, Tan CW et al. Whole blood impedance aggregometry detects heparin-induced thrombocytopenia antibodies. Thromb Res 2010; 125: e234–e239.

39. Morel-Kopp MC, Tan CW, Brighton TA et al. ASTH Clinical Trials Group. Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study. Thromb Haemost 2012; 107: 575–583.